Form Bio announced the ability for CGT firms to swiftly model billions of potential construct candidates.
In recent years, base editing, an emerging extension of the renowned CRISPR/Cas 9 technology, has gained traction within the biotech community. Now, for the first time in the United States, base editing has entered clinical trials.
Form Bio, the provider of advanced computational life sciences technology, announced today capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates.
The biotech sector in Texas is experiencing remarkable growth, establishing itself as a vibrant hub that unites scientific minds from all corners of the United States.